Fluzoparib plus apatinib versus physician-selected chemotherapy for HRD-positive, HER2-negative advanced breast cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, open-label, phase III trial comparing the oral PARP inhibitor fluzoparib plus the anti-angiogenic agent apatinib against investigator-selected chemotherapy in patients with HRD-positive, HER2-negative metastatic breast cancer. Eligible patients are adults with HER2-negative disease who test HRD-positive (BRCA1/2 mutation or HRD score ≥42) and have received no more than two prior lines of chemotherapy for metastatic disease. The trial builds on preclinical data and prior ovarian cancer work suggesting synergy between PARP inhibition and anti-angiogenesis, aiming to expand targeted combination therapy beyond BRCA-mutant cases. Outcomes will determine whether this combination improves clinical benefit compared with standard chemotherapy in this biomarker-selected population.

Why it matters

Who can join: the full rules

Inclusion criteria

The subjects must meet all of the following conditions:

Adult female patients (aged 18 to 70 years) with metastatic breast cancer diagnosed by pathology or imaging; 2) Pathological confirmation of HER2 negative (definition: immunohistochemical result is 0 or + or ++ and in situ hybridization result is negative); 3) The patient's HRD test was positive (definition: BRCA1/2 mutation, or HRD score greater than or equal to 42 points); 4) HR+/HER2- patients who have received endocrine therapy during the metastasis stage; 5) Having received no more than two lines of chemotherapy (or ADC) regimens for metastatic breast cancer in the past; 6) Evaluation of anti-tumor treatment (including chemotherapy /HER2-ADC/TROP2-ADC) for 6-8 cycles to achieve clinical benefit (CR or PR) or SD for 24 weeks or more; 7) ECOG physical condition score ≤2 points, and the expected survival period is no less than 3 months; 8) At least one measurable lesion was found in the imaging examination within 2 weeks before enrollment. Or simple bone metastasis lesion; 9) At the time of enrollment, the previous treatment-related toxicity must be remitted to NCI CTCAE (Version 5.0) ≤1 degree (except for alopecia or other toxicities that the investigator deems to pose no risk to the patient's safety).

10\) Adequate bone marrow functional reserve:

1. White blood cell count (WBC) ≥3.0×10\^9 / L
2. Neutrophil count (ANC) ≥1.5×10\^9 / L
3. Platelet count (PLT) ≥70×10\^9 / L 11) Liver, kidney and heart function tests are basically normal (based on the normal values in the laboratories of each research center) :

a. Total bilirubin (TBIL) ≤3× upper limit of normal (ULN) b. Alanine aminotransferase and aspartate aminotransferase (ALT/AST) ≤2.5×ULN (≤5 ×ULN for patients with liver metastasis) c. Serum creatinine ≤1.5×ULN or creatinine clearance rate (Ccr) ≥60 ml/min; d.Left ventricular ejection fraction (LVEF) ≥ 55%, e. QTcF(Fridericia correction) ≤ 470 ms. 12) Be able to understand the research process, voluntarily participate in this research, and sign the informed consent form.

Exclusion Criteria

If a subject experiences any of the following situations, they will not be eligible to participate in this study:

1. Patients with HR+/ HER2-MBC who have not received endocrine therapy before;
2. Has not received any treatment for metastatic breast cancer;
3. Received more than two chemotherapy regimens for metastatic breast cancer;
4. Patients who are known to be allergic to the active ingredient or other ingredients of the investigational drug.
5. Pregnant or lactating women, and women of childbearing age who refused to take effective contraceptive measures during the study period.
6. Those with severe heart disease or discomfort, expected to be unable to tolerate chemotherapy, including but not limited to: fatal arrhythmia or higher-grade atrioventricular block, unstable angina pectoris, clinically significant valvular heart disease, electrocardiogram showing transmural myocardial infarction, uncontrollable hypertension;
7. Any other circumstances where the researcher deems the patient unsuitable for participation in this study, any concomitant diseases or conditions that may interfere with participation in the study, or any serious medical conditions that may affect the safety of the subjects (such as uncontrollable heart disease, hypertension, active or uncontrollable infection, active hepatitis B virus infection).

Where it's running

• Sun Yat Sen Memorial Hospital，Sun Yat sen University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Principal investigator: Jianli Zhao — Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
• Study coordinator: Zhao Jianli
• Email: zhaojli5@mail.sysu.edu.cn
• Phone: 86-20-34070870

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• First-line combo therapy with GnP, SHR-1701, and Apatinib for metastatic pancreatic cancer

  This trial tests whether adding SHR-1701 and Apatinib to standard GnP can safely and effectively treat previously untreated metastatic pancreatic cancer.

  Recruiting Phase 1/2 West China Hospital · Chengdu, Sichuan · NCT07802184

• A combination therapy for advanced second-line gastric cancer using apatinib with albumin-bound paclitaxel, with or without adebrelimab

  This study tests whether adding adebrelimab to a regimen of apatinib and albumin-bound paclitaxel helps patients with advanced gastric or gastroesophageal junction cancer who did not respond to first-line therapy.

  Recruiting Phase 2 The First Affiliated Hospital of Zhengzhou University · Zhengzhou, Henan · NCT07770113

• VRT106 plus camrelizumab and apatinib for advanced HCC in patients who have tried prior ICIs

  This study tests VRT106, with camrelizumab and apatinib, to see if it helps people with advanced hepatocellular carcinoma who have already had prior immune checkpoint inhibitors fail.

  Recruiting Phase 2/3 Guangzhou Virotech Pharmaceutical Co., Ltd. · Guangzhou, Guangdong · NCT07589244

• Alternating liver-artery and IV chemotherapy with optional adebrelimab and apatinib for unresectable biliary tract cancer

  This study will test whether alternating hepatic arterial infusion chemotherapy and standard IV gemcitabine–cisplatin, with or without the immunotherapy adebrelimab and the targeted drug apatinib, helps people with unresectable biliary tract cancer shrink tumors and live longer.

  Recruiting Phase 2 Air Force Military Medical University, China · Xi'an, Shaanxi · NCT07569679

• Apatinib plus liposomal irinotecan for refractory or metastatic osteosarcoma

  This trial tests whether combining the oral drug apatinib with intravenous liposomal irinotecan helps patients whose osteosarcoma has progressed after standard chemotherapy.

  Recruiting Phase 1/2 Peking University People's Hospital · Beijing · NCT07479732

• Shr-1701 with or without Apatinib plus chemotherapy as neoadjuvant treatment for gastric cancer

  This trial tests whether adding SHR-1701, with or without apatinib, to chemotherapy before surgery helps patients with resectable locally advanced gastric or gastroesophageal junction cancer.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07464756

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.